| NCT01987895 | Actelion | Clostridium Difficile Infection | 2014-03-27 | PHASE3 |
| NCT02344511 | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Osteomyelitis | 2016-03 | PHASE3 |
| NCT06126614 | Hamilton Health Sciences Corporation|McMaster University|Ontario Clinical Oncology Group (OCOG) | Periprosthetic Joint Infection | 2024-05-07 | PHASE3 |
| NCT00423657 | Forest Laboratories | Bacterial Infections | 2007-03 | PHASE3 |
| NCT00451373 | National Taiwan University Hospital | Acute Renal Failure|Sepsis|Postoperative | 2006-07 | NA |
| NCT00003805 | European Organisation for Research and Treatment of Cancer - EORTC | Bone Marrow Suppression|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific | 1997-11 | PHASE3 |
| NCT00811980 | University of Utah|Pfizer | Sepsis | 2009-01 | |
| NCT04917627 | Hamad General Hospital | Wound Infection | 2021-05-01 | PHASE4 |
| NCT04044703 | Murdoch Childrens Research Institute|Royal Children´s Hospital|Royal Hospital For Women|University of Otago|Sydney Children´s Hospitals Network|Monash Health | Sepsis|Infection|Bacteremia | 2019-08-30 | PHASE4 |
| NCT01792804 | Heinrich-Heine University, Duesseldorf|German Research Foundation | Staphylococcus Aureus Infection | 2013-12 | PHASE3 |
| NCT02618187 | Seres Therapeutics, Inc. | Ulcerative Colitis | 2016-01-13 | PHASE1 |
| NCT05320068 | Julia Orígüen|Instituto de Salud Carlos III | Clostridioides Difficile Infection | 2022-08-02 | PHASE3 |
| NCT02092935 | Summit Therapeutics|Wellcome Trust | Clostridium Difficile Infection | 2014-04 | PHASE2 |
| NCT02216227 | VA Office of Research and Development | Surgical Site Infection | 2014-04-01 | NA |
| NCT02865616 | NuBiyota | Clostridium Difficile Infection | 2017-10-27 | PHASE1 |
| NCT04775953 | National Institute of Allergy and Infectious Diseases (NIAID) | Staphylococcal Bacteraemia | 2021-04-22 | PHASE2 |
| NCT01232595 | Novartis Pharmaceuticals | Moderate Clostridium Difficile Infection | 2010-10 | PHASE2 |
| NCT03595553 | Summit Therapeutics | Clostridioides Difficile Infection | 2019-01-28 | PHASE3 |
| NCT01196169 | Mountain Home Research & Education Corporation|East Tennessee State University|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Staphylococcal Infections|Methicillin-resistant Staphylococcus Aureus | 2010-10 | PHASE4 |
| NCT05376228 | University Hospital Birmingham NHS Foundation Trust | Inflammatory Bowel Diseases|Primary Sclerosing Cholangitis | 2022-02-01 | |
| NCT07547826 | Assiut University | Hydrocephalus|Ventriculoperitoneal Shunt Infection|Surgical Site Infection (SSI)|Cerebrospinal Fluid Shunt Infection|Pediatric Hydrocephalus|Hydrocephalus in Children|Hydrocephalus in Infants|Postoperative Complications|Prosthesis-Related Infections|Bacterial Infections and Mycoses | 2026-05 | PHASE4 |
| NCT02355938 | Baylor College of Medicine|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile|Spinal Cord Injury | 2014-02 | PHASE4 |
| NCT01977989 | University of Tennessee|Semmes-Murphey Foundation | Wound Infection | 2013-10 | PHASE4 |
| NCT03796650 | Oslo University Hospital|South-Eastern Norway Regional Health Authority|University Hospital of North Norway|Haukeland University Hospital|Helse Nord-Tr?ndelag HF|Vestre Viken Hospital Trust|The Hospital of Vestfold|Sykehuset Telemark|Alesund Hospital|University Hospital, Akershus|Lovisenberg Diakonale Hospital|Sorlandet Hospital HF|Ostfold Hospital Trust|Diakonhjemmet Hospital|Nordlandssykehuset HF|Sykehuset Innlandet HF|Helse Stavanger HF | Clostridium Difficile Infection | 2019-07-17 | PHASE3 |
| NCT02426918 | Debiopharm International SA | Bacterial Infections | 2015-05 | PHASE2 |
| NCT03710122 | Elizabeth Carey|Arizona State University | Primary Sclerosing Cholangitis | 2020-01-23 | PHASE2|PHASE3 |
| NCT01184872 | Novartis Pharmaceuticals | Infections | 2010-03 | PHASE3 |
| NCT04825522 | Windsor-Essex Compassionate Care Community|Cairo University | Spine Disease | 2022-03-27 | PHASE4 |
| NCT04238923 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s | Vascular Diseases|Peripheral Vascular Disease|Surgical Site Infection|Bypass Complication | 2020-05-01 | PHASE2|PHASE3 |
| NCT01918813 | Chikara Tashiro | Inflammatory Bowel Disease|Hepatobiliary Disease|Pancreas Disease | 2009-11 | NA |
| NCT03964493 | TenNor Therapeutics Limited | Skin and Subcutaneous Tissue Bacterial Infections|Gram-Positive Bacterial Infections | 2019-04-20 | PHASE2 |
| NCT05535725 | Clinique Ortos | Surgical Site Infection | 2019-10-10 | PHASE4 |
| NCT07478848 | Abramson Cancer Center at Penn Medicine|National Cancer Institute (NCI) | Large B Cell Lymphoma|Non Hodgkin Lymphoma (NHL)|Diffuse Large B Cell Lymphoma (DLBCL)|Diffuse Large B Cell Lymphoma Refractory|Diffuse Large B Cell Lymphoma Relapsed | 2026-04-07 | PHASE1 |
| NCT04678154 | Major Extremity Trauma Research Consortium|United States Department of Defense | Post Operative Surgical Site Infection | 2021-05-07 | PHASE3 |
| NCT00061633 | Cumberland Pharmaceuticals | Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections | 2003-06 | PHASE2 |
| NCT02732327 | Forest Laboratories | Neoplasms|Febrile Neutropenia | 2016-05-17 | PHASE2 |
| NCT02694458 | Assistance Publique - H?pitaux de Paris|URC-CIC Paris Descartes Necker Cochin | Methicillin-resistant Staphylococcal Infections | 2016-02-23 | NA |
| NCT03685747 | Thomas Jefferson University | Peritoneal Dialysis-associated Peritonitis | 2018-11-15 | PHASE1 |
| NCT04816968 | Ospedale San Carlo Borromeo|Associazione Oncologica Milanese AmoLaVita ONLUS | Severe Bacterial Infections | 2021-09 | PHASE1 |
| NCT05690048 | Michael Dill|National Center for Tumor Diseases, Heidelberg|German Cancer Research Center|Heidelberg University|University of Cologne|Universit?tsmedizin Mannheim | Immunotherapy|HCC - Hepatocellular Carcinoma | 2025-07-16 | PHASE2 |
| NCT00251017 | National Taiwan University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) | Adverse Effects | 2005-07 | NA |
| NCT00314951 | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Infections|Diarrhea | 2006-05-02 | PHASE3 |
| NCT06817031 | International Centre for Diarrhoeal Disease Research, Bangladesh|Bill and Melinda Gates Foundation | Environmental Enteric Dysfunction | 2025-04-20 | PHASE2 |
| NCT04995653 | Seres Therapeutics, Inc.|Memorial Sloan Kettering Cancer Center | Allogeneic Hematopoietic Stem Cell Transplantation | 2021-11-24 | PHASE1 |
| NCT00911573 | Wyeth is now a wholly owned subsidiary of Pfizer | Skin Diseases|Infection | 2011-08 | PHASE3 |
| NCT02774382 | Hvidovre University Hospital | Clostridium Difficile | 2017-05-01 | PHASE3 |
| NCT01975662 | Singapore General Hospital|Singapore Clinical Research Institute | Bacteremia Due to Staphylococcus Aureus | 2014-01 | PHASE2 |
| NCT03678142 | University Hospital, Basel, Switzerland | Antibiotic Drug Concentration in Sweat | 2018-10-01 | |
| NCT04246151 | Hamilton Health Sciences Corporation | Clostridium Difficile Colonization|Clostridium Difficile Diarrhea | 2022-09-01 | EARLY_PHASE1 |
| NCT07300553 | Assistance Publique - H?pitaux de Paris|INSERMUMR938|CRB SAT APHP.SU Saint-Antoine hospital | IBD|Crohn Disease|Ulcerative Colitis (UC) | 2026-01-02 | PHASE2 |
| NCT04025567 | National Cancer Institute (NCI) | Metastatic Hepatocellular Carcinoma|Hepatocellular Carcinoma | 2020-03-12 | PHASE2 |
| NCT06747611 | University of Minnesota|Columbia University | Alopecia Areata|Alopecia Totalis|Alopecia Universalis | 2025-08-21 | PHASE2 |
| NCT01372371 | Ganga Hospital | Infection | 2011-06 | NA |
| NCT04042077 | Menarini Group | Surgical Site Infection | 2019-09-25 | PHASE3 |
| NCT02443064 | Zhejiang University|Shengjing Hospital|Tianjin Medical University Cancer Institute and Hospital|Qilu Hospital of Shandong University|First Affiliated Hospital, Sun Yat-Sen University|Guangzhou General Hospital of Guangzhou Military Command|The First Affiliated Hospital of Soochow University|The First Affiliated Hospital with Nanjing Medical University|Zhejiang Provincial Hospital of TCM|Second Affiliated Hospital, School of Medicine, Zhejiang University | Blood Stream Infections|Endocarditis|MRSA | 2014-01 | PHASE4 |
| NCT01226992 | University Health Network, Toronto | Recurrent Clostridium Difficile Infection|Laboratory Confirmed Clostridium Difficile Infection | 2010-10 | PHASE2|PHASE3 |
| NCT07221708 | University of Maryland, Baltimore|University of Maryland, Baltimore Washington Medical Center | Clostridioides Difficile|Vancomycin Resistance Enterococcus Faecium | 2026-03-01 | PHASE2|PHASE3 |
| NCT03200093 | Rochester General Hospital | Clostridium Difficile Infection | 2017-06-08 | PHASE4 |
| NCT00107978 | Cumberland Pharmaceuticals | Staphylococcal Skin Infection | 2005-02 | PHASE3 |
| NCT03412500 | Pinyo Rattanaumpawan | Methicillin-Resistant Staphylococcus Aureus | 2016-10 | PHASE4 |
| NCT01623817 | Samsung Medical Center | Infection | 2012-06 | NA |
| NCT04666948 | University Hospital, Ghent|Belgium Health Care Knowledge Centre|University Ghent | Vancomycin | 2020-12-28 | PHASE4 |
| NCT05077085 | Leiden University Medical Center|OLVG|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Medical Center Haaglanden | Clostridium Infections|Clostridioides Difficile|Enterocolitis, Pseudomembranous | 2022-01 | PHASE4 |
| NCT02284126 | Columbia University|Agency for Healthcare Research and Quality (AHRQ)|Cornell University|Icahn School of Medicine at Mount Sinai | Infection|Surgery|Nervous System Diseases | 2014-10 | PHASE3 |
| NCT07134790 | University Ghent|Institut de Recherche en Sciences de la Santé (IRSS)|Agence de Formation, de Recherche & d´Expertise en Santé pour l´Afrique (AFRICSanté)|Bill and Melinda Gates Foundation | Environmental Enteric Dysfunction (EED) | 2025-07-30 | PHASE2 |
| NCT07341282 | McMaster University|Weston Family Foundation | Ulcerative Colitis (UC)|Primary Sclerosing Cholangitis (PSC) | 2026-01 | PHASE2 |
| NCT06189885 | Chang Gung Memorial Hospital | Periprosthetic Joint Infection | 2024-08-01 | NA |
| NCT01085760 | Mayo Clinic|PSC Partners Seeking a Cure | Primary Sclerosing Cholangitis | 2010-02 | PHASE1 |
| NCT01775397 | Astellas Pharma Europe Ltd.|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile | 2012-11-29 | PHASE4 |
| NCT02667418 | VA Office of Research and Development | Clostridium|Difficile|Fidaxomicin|Vancomycin | 2016-02-19 | PHASE4 |
| NCT06637332 | Todd C. Lee MD MPH FIDSA|University of Melbourne|The Peter Doherty Institute for Infection and Immunity | Staphylococcus Aureus Septicemia|Staphylococcus Aureus Bacteremia|S. Aureus Bacteremia|S. Aureus Bloodstream Infection|Staphylococcus Aureus Endocarditis | 2024-11-14 | PHASE4 |
| NCT03839914 | The University of Hong Kong | Spinal Deformity|Trauma|Spinal Tumor|Surgical Site Infection | 2020-08-01 | NA |
| NCT00435305 | University Hospital Tuebingen | Pneumonia|Bacteremia | 2006-11 | |
| NCT00150852 | University Hospital, Geneva | Wound Infection | 2004-09 | PHASE2 |
| NCT02631408 | Orthopedic Hospital Vienna Speising | Spinal Fusion Acquired | 2015-08 | PHASE4 |
| NCT04993027 | Alberta Hip and Knee Clinic|University of Calgary | Infection of Total Hip Joint Prosthesis|Infection of Total Knee Joint Prosthesis | 2025-12-30 | PHASE2 |
| NCT06954129 | University of Pennsylvania | Acute Kidney Injury | 2026-01-28 | PHASE4 |
| NCT00442832 | Theravance Biopharma | Staphylococcal Skin Infection | 2006-12 | PHASE2 |
| NCT04731025 | Mikkel Herly|University of Copenhagen|Herlev and Gentofte Hospital|Zealand University Hospital|Odense University Hospital|Vejle Hospital|Esbjerg Hospital - University Hospital of Southern Denmark|Aarhus University Hospital|Aalborg University Hospital | Implant Complication|Implant Infection|Implant Site Infection|Implant Capsular Contracture|Implant Site Pocket Infection|Implant Expulsion|Antibiotic Side Effect | 2021-01-27 | PHASE3 |
| NCT03939273 | Radboud University Medical Center | Systemic Inflammatory Response Syndrome|Postoperative Shock|Coronary Artery Disease|Extracorporeal Circulation; Complications | 2022-03 | NA |
| NCT00324922 | University of Washington | Osteomyelitis|Methicillin-resistant Staphylococcus Aureus | 2006-05-01 | PHASE3 |
| NCT05693077 | Leiden University Medical Center | Clostridioides Difficile Infection | 2023-09-22 | PHASE1 |
| NCT03221023 | University of British Columbia | Vancomycin|Implantable Neural Stimulator|Deep Brain Stimulation|Surgical Site Infection | 2017-09-15 | PHASE2|PHASE3 |
| NCT02582203 | Wayne State University|Henry Ford Hospital|St. John Providence Health System|Detroit Medical Center|Forest Laboratories | Skin Diseases, Infectious|Staphylococcal Skin Infections | 2012-02 | PHASE4 |
| NCT02154061 | Emory University | Influenza | 2015-04 | NA |
| NCT00770341 | Merck Sharp & Dohme LLC | Staphylococcal Infection | 2008-09 | PHASE3 |
| NCT03617445 | University of Wisconsin, Madison|National Institute of Allergy and Infectious Diseases (NIAID) | Clostridium Difficile Infection Recurrence | 2022-08-03 | PHASE2 |
| NCT03426761 | Infectious Diseases Physicians, Inc.|Johns Hopkins University | Bone Infection|Osteomyelitis|Septic Arthritis|Joint Infection|Prosthetic Joint Infection | 2018-01-25 | PHASE4 |
| NCT02208063 | Cumberland Pharmaceuticals | Bacteremia | 2014-12 | PHASE3 |
| NCT00062647 | Cumberland Pharmaceuticals | Gram-Positive Bacterial Infections | 2003-08 | PHASE2 |
| NCT04247542 | Acurx Pharmaceuticals Inc. | Clostridium Difficile Infection | 2020-03-06 | PHASE2 |
| NCT00529282 | Basilea Pharmaceutica | Fever|Neutropenia|Gram-positive Bacterial Infections|Pseudomonas Infection | 2007-10 | PHASE3 |
| NCT07338773 | Ba?ak?ehir ?am & Sakura City Hospital | Diabetic Foot Disease|Diabetic Foot Infection|Diabetic Amputation Foot Wound | 2025-09-03 | PHASE4 |
| NCT03928522 | Washington University School of Medicine | Total Knee Replacement | 2019-01-28 | PHASE4 |
| NCT06503978 | Gut-Brain-Axis Therapeutics Inc. | Autism Spectrum Disorder|Gastro-Intestinal Disorder|Constipation|Diarrhea | 2024-08-20 | PHASE2 |
| NCT03546829 | Abramson Cancer Center at Penn Medicine | Early Stage Non-Small Cell Lung Cancer | 2019-03-05 | PHASE1 |
| NCT06439953 | Rhode Island Hospital | Post-Op Complication|Spine Surgery|Site Infection|Surgical Site Infection|Spinal Instrumentation|Index Spinal Instrumentation|Layer-by-Layer Closure|Locoregional Flap-Based Closure | 2024-10-01 | NA |
| NCT02210169 | Murdoch Childrens Research Institute|Royal Children´s Hospital|Royal Hospital For Women | Sepsis|Infection|Bacteremia | 2014-09 | NA |
| NCT01561469 | Pfizer|University of Louisville|Henry Ford Hospital|Summa Health System|Sparrow Health System|Jackson Health System | Methicillin-Resistant Staphylococcus Aureus (MRSA)|Hospital-Acquired Pneumonia | 2008-11 | |
| NCT03403972 | Seoul National University Hospital | Simvastatin Pharmacokinetics and Gut Microbiome | 2017-12-06 | PHASE1 |
| NCT01633762 | University Hospital, Gentofte, Copenhagen|University of Copenhagen|Steno Diabetes Center Copenhagen|Rigshospitalet, Denmark | Diabetes|Obesity|Osteoporosis|Inflammation | 2012-04 | EARLY_PHASE1 |
| NCT07490054 | Melana Yuzefpolskaya, MD | Chronic Heart Failure | 2025-09-01 | PHASE1 |
| NCT01290237 | Boston Children´s Hospital | Infection | 2011-02 | NA |
| NCT01746095 | Savara Inc.|Synteract, Inc.|Cystic Fibrosis Foundation | Cystic Fibrosis | 2013-03 | PHASE2 |
| NCT04968951 | Ari M Grinspan | Ulcerative Colitis|FMT|Fecal Microbiota Transplant | 2021-11-10 | EARLY_PHASE1 |
| NCT00915967 | Oregon Health and Science University | Surgical Wound Infections | 2009-05-13 | NA |
| NCT07435051 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Osteomyelitis (Refractory) | 2026-05-01 | PHASE3 |
| NCT06384651 | The Methodist Hospital Research Institute | Infections|Ankle Arthritis | 2024-12-03 | PHASE4 |
| NCT00304811 | Michael E. DeBakey VA Medical Center|Baylor College of Medicine | Staphylococcus Aureus | 2006-01 | PHASE4 |
| NCT00861887 | Corewell Health East|Beaumont Hospital | Clostridium Difficile Colitis | 2009-02 | NA |
| NCT04236778 | Vedanta Biosciences, Inc. | Healthy Volunteers | 2017-11-28 | PHASE1 |
| NCT01339091 | Durata Therapeutics Inc., an affiliate of Allergan plc | Abscess|Wound Infection|Surgical Site Infection|Cellulitis | 2011-03 | PHASE3 |
| NCT00462878 | PETHEMA Foundation | Allogenic Blood Stem Cell Transplantation|Febrile Neutropenia | 2002-11 | |
| NCT05876182 | University of Milano Bicocca|Genetic s.p.a. | Primary Sclerosing Cholangitis|Liver and Intrahepatic Bile Duct Disorder|IBD | 2023-06-15 | PHASE2 |
| NCT06166381 | University of Duhok | Infection, Bacterial | 2024-01-25 | NA |
| NCT03721328 | Osteal Therapeutics, Inc. | Prosthetic Joint Infection | 2018-10-26 | PHASE2 |
| NCT03030248 | Medical College of Wisconsin | Clostridium Difficile Infection|Hematologic Diseases|Bone Marrow Transplant|Oncologic Disorders | 2018-06-01 | PHASE2 |
| NCT03585426 | Xijing Hospital | Vancomycin | 2016-03 | PHASE4 |
| NCT04771884 | Shandong University|Children´s Hospital of Chongqing Medical University | Bacterial Meningitis|Augmented Renal Clearance | 2020-10-01 | |
| NCT03438214 | University of Sao Paulo | Gram-Positive Bacterial Infections|Nephrotoxicity|Sepsis | 2018-04-28 | PHASE4 |
| NCT04000555 | University of South Florida | Clostridium Difficile Infection|Clostridium Difficile Infection Recurrence | 2019-09-01 | PHASE4 |
| NCT01867138 | Hospital Italiano de Buenos Aires | Nosocomial Neonatal Sepsis | 2007-03 | PHASE3 |
| NCT05370885 | Vedanta Biosciences, Inc. | Ulcerative Colitis|Colitis, Ulcerative | 2023-05-08 | PHASE2 |
| NCT01537666 | Savara Inc.|INC Research Limited | Healthy|Cystic Fibrosis | 2011-11 | PHASE1 |
| NCT02096536 | Universitaire Ziekenhuizen KU Leuven | Neonatal Infection | 2014-04 | PHASE4 |
| NCT01669980 | Forest Laboratories | Infections|Pneumonia | 2012-10 | PHASE4 |
| NCT01363271 | Pfizer|University of Maryland|Lodise & Lodise, LLC | Complicated Skin and Structure Infection|Nosocomial Pneumonia | 2011-05 | |
| NCT06567808 | Hamilton Health Sciences Corporation|Canadian Institutes of Health Research (CIHR) | Infection, Surgical Site | 2026-03-01 | PHASE4 |
| NCT00037050 | Pfizer | Bacterial Infections|Gram-Positive Bacterial Infections|Bacteremia | 2002-04 | PHASE3 |
| NCT03827447 | Medical College of Wisconsin | Clostridium Difficile Infection | 2019-07-17 | PHASE1 |
| NCT07220967 | Memorial Sloan Kettering Cancer Center | Breast Cancer | 2025-10-21 | PHASE4 |
| NCT01592032 | Clinica Universidad de Navarra, Universidad de Navarra|University of Navarrra Hospital (Clinica Universitaria) | Catheter-Related Infections|Bacteremia. | 2012-05 | PHASE4 |
| NCT01287832 | St. John Health System, Michigan|Henry Ford Health System|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Bacteremia | 2011-06 | PHASE4 |
| NCT01734694 | Henry Ford Health System | Health Care Associated Pneumonia|Osteomyelitis+Septic Arthritis|Endocarditis|Bacteremia|Acute Bacterial Skin and Skin Structure Infections | 2011-10 | PHASE4 |
| NCT03105479 | Actelion | Clostridium Difficile Infection | 2017-04-14 | PHASE2|PHASE3 |
| NCT02926846 | Alice Ho Miu Ling Nethersole Hospital | Peritonitis|Kidney Failure | 2014-03 | PHASE4 |
| NCT05256693 | Assistance Publique - H?pitaux de Paris|GIRCI Ile de France | Clostridium Difficile Infections|Stem Cell Transplant Complications | 2022-03 | PHASE3 |
| NCT04182633 | Arizona State University|University of Minnesota | Autism Spectrum Disorder|Gastro-Intestinal Disorder|Constipation|Diarrhea | 2019-11-15 | PHASE2 |
| NCT04208958 | Vedanta Biosciences, Inc.|Bristol-Myers Squibb | Metastatic Cancer|Melanoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Colorectal Cancer | 2020-01-23 | PHASE1|PHASE2 |
| NCT03806543 | Southeast University, China | Vancomycin | 2015-01-01 | |
| NCT04899115 | Patricia Bloom|Vedanta Biosciences, Inc.|American College of Gastroenterology|American Association for the Study of Liver Diseases | Cirrhosis|Hepatic Encephalopathy | 2021-08-06 | PHASE2 |
| NCT00077675 | Cumberland Pharmaceuticals | Infections, Gram-positive Bacterial | 2004-02 | PHASE2 |
| NCT02573064 | Maimónides Biomedical Research Institute of Córdoba | Acinetobacter Infections | 2010-01 | |
| NCT05137119 | University of Melbourne|Berry Consultants|McGill University Health Centre+Research Institute of the McGill University Health Centre|Menzies School of Health Research|Aotearoa Clinical Trials|Queensland University of Technology|Sunnybrook Health Sciences Centre|Tan Tock Seng Hospital|Telethon Kids Institute|The Peter Doherty Institute for Infection and Immunity|The University of Queensland|UMC Utrecht|Radboud University Medical Center|King´s College London|Rambam Health Care Campus|University College, London|The Methodist Hospital Research Institute | Staphylococcus Aureus Bacteremia | 2022-02-16 | PHASE4 |
| NCT00084266 | Pfizer | Methicillin Resistant Staphylococcus Aureus (MRSA) | 2004-10 | PHASE4 |
| NCT02340182 | W.J. Wiersinga, MD, PhD|ZonMw: The Netherlands Organisation for Health Research and Development | Healthy|Sepsis | 2013-03 | NA |
| NCT04948814 | Tongji Hospital | Autism Spectrum Disorder | 2022-06-01 | PHASE1 |
| NCT02127749 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Endotoxemia | 2014-06 | NA |
| NCT02179658 | Astellas Pharma Inc | Clostridium Difficile | 2014-06-23 | PHASE3 |
| NCT01594827 | Johns Hopkins University|Case Western Reserve University|Cystic Fibrosis Foundation | Cystic Fibrosis | 2012-10 | PHASE2 |
| NCT03785210 | National Cancer Institute (NCI) | Hepatocellular Carcinoma|Hepatocellular Cancer|Metastatic Pancreatic Cancer|Metastatic Colorectal Cancer|Liver Metastasis | 2019-06-05 | PHASE2 |
| NCT02464020 | University of Minnesota | Primary Sclerosing Cholangitis|Inflammatory Bowel Disease | 2015-07 | PHASE1 |
| NCT02730962 | University of Minnesota | Pre-Diabetes | 2016-06 | PHASE2 |
| NCT00424190 | Forest Laboratories | Bacterial Infections | 2007-02 | PHASE3 |
| NCT02478710 | Wright State University | Pneumonia, Ventilator-Associated | 2015-06 | PHASE4 |
| NCT00228982 | Basilea Pharmaceutica | Skin Diseases, Infectious|Skin Diseases, Bacterial|Staphylococcal Skin Infections | 2004-10 | PHASE3 |
| NCT06373640 | University Hospital Southampton NHS Foundation Trust | Subarachnoid Hemorrhage | 2024-11 | NA |
| NCT05338008 | The Affiliated Hospital of Qingdao University | Hip | 2022-05-01 | NA |
| NCT03427229 | Catholic University of the Sacred Heart | Clostridium Difficile|Pseudomembranous Colitis | 2016-03 | PHASE2 |
| NCT00430937 | Novartis Pharmaceuticals | Skin Diseases, Infectious|Soft Tissue Infections | 2006-04 | PHASE3 |
| NCT02609646 | Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva | Critical Illness|Infection | 2016-01 | |
| NCT03107169 | Universidad Autonoma de Nuevo Leon | Clostridium Difficile Infection | 2015-02-01 | NA |
| NCT06527131 | Cairo University | Charcot Foot Ulcer | 2024-07 | NA |
| NCT02057198 | Duke University | C. Difficile|Diarrhea|Enterocolitis | 2014-06-10 | PHASE4 |
| NCT00269399 | Bausch Health Americas, Inc. | Clostridium Infections|Diarrhea | 2005-12 | PHASE3 |
| NCT00543608 | Arpida AG | Hospital-Acquired Pneumonia|Ventilator-Associated Pneumonia|Health-Care-Associated Pneumonia | 2007-11 | PHASE2 |
| NCT02607618 | Motif Bio | Skin Structures and Soft Tissue Infections | 2015-11 | PHASE3 |
| NCT06540391 | Microbiotica Ltd|Merck Sharp & Dohme LLC | Melanoma | 2024-08-28 | PHASE1 |
| NCT03157388 | University of Aarhus | Alcoholic Hepatitis | 2017-06-01 | NA |
| NCT05766670 | Wake Forest University Health Sciences | Open tíbia Fracture|Osteomyelitis Tibia|Tibial Fractures | 2024-04-08 | PHASE3 |
| NCT03809260 | Seoul National University Hospital | Human Microbiome | 2018-12-01 | NA |
| NCT02743234 | University of Aarhus | Clostridium Difficile Infection | 2016-04 | PHASE3 |
| NCT02400112 | University of Tennessee | Fractures, Open|Surgical Wound Infection | 2015-03 | PHASE4 |
| NCT03673956 | Mayo Clinic | Chronic Rhinosinusitis (Diagnosis) | 2018-09-26 | PHASE1|PHASE2 |
| NCT06661772 | Benha University | Critically Ill Children|Sepsis | 2024-06-01 | |
| NCT00612469 | Universidade Federal do Ceara | Dental Caries | 2005-10 | NA |
| NCT02951702 | St. Luke´s Hospital, Chesterfield, Missouri | Clostridium Difficile Infection|Prophylaxis|Vancomycin | 2016-11 | PHASE4 |
| NCT01157533 | M.D. Anderson Cancer Center | Infection | 2010-06 | NA |
| NCT03388268 | Washington University School of Medicine | Clostridium Difficile Infection|Diarrhea | 2017-12-29 | PHASE4 |
| NCT02764359 | CAMC Health System | Infection|Sepsis|Obesity | 2016-08-01 | NA |
| NCT02432807 | Kurobe LLC | Bacterial Conjunctivitis | 2015-05 | PHASE3 |
| NCT06979609 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Clostridioides Difficile Infection|Clostridioides Difficile Infection Recurrence|Clostridoides Difficile Associated Disease | 2025-10-01 | PHASE2|PHASE3 |
| NCT02301221 | Jinling Hospital, China | Slow Transit Constipation | 2015-03 | PHASE2 |
| NCT01878643 | Stony Brook University | Respiratory Infection|Bacterial Resistance|Respiratory Failure | 2001-12 | EARLY_PHASE1 |
| NCT01942447 | University Hospital Tuebingen | Clostridium Difficile|Clostridium Difficile Infection | 2013-10 | NA |
| NCT00295178 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Cellulitis | 2006-02-20 | PHASE4 |
| NCT03506347 | Mayo Clinic | Arthropathy of Knee Joint | 2018-09-24 | PHASE2|PHASE3 |
| NCT07282782 | University of California, San Diego | Total Knee Arthroplasty | 2024-06-10 | PHASE4 |
| NCT04729322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Metastatic Colorectal Adenocarcinoma|Metastatic Small Intestinal Adenocarcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8 | 2021-02-22 | PHASE2 |
| NCT04673877 | Mayo Clinic | Infection|Hand Injury Wrist|Hand Injuries|Hand Injuries and Disorders|Hand Arthritis | 2021-08-26 | PHASE1 |
| NCT05535075 | University Hospital, Ghent | Vancomycin | 2021-11-12 | PHASE4 |
| NCT05571722 | Assistance Publique Hopitaux De Marseille | Antibiotic Prophylaxis|General Surgery | 2024-11-12 | PHASE4 |
| NCT00945152 | Robert S Berman MD | Bacterial Infections|Wounds | 2011-07-15 | PHASE2 |
| NCT01811732 | Melinta Therapeutics, Inc. | Skin and Subcutaneous Tissue Bacterial Infections | 2013-04 | PHASE3 |
| NCT01133600 | Clinical Alliance for Research & Education - Infectious Diseases, LLC.|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Diabetic Foot | 2010-08 | PHASE4 |
| NCT01952834 | Medical College of Wisconsin | Coronary Artery Disease | 2013-06 | PHASE4 |
| NCT01400867 | Forest Laboratories|AstraZeneca | Infections, Pediatrics | 2011-12 | PHASE2|PHASE3 |
| NCT04401553 | University of Texas Southwestern Medical Center | Surgical Site Infection|Beta-lactam Allergy | 2024-08-16 | PHASE4 |
| NCT01983683 | Actelion | Clostridium Difficile Infection | 2013-12-12 | PHASE3 |
| NCT05539729 | Icahn School of Medicine at Mount Sinai|Doris Duke Charitable Foundation | Multiple Sclerosis | 2023-01-31 | PHASE1 |
| NCT04756895 | CR-CSSS Champlain-Charles-Le Moyne | Vancomycin|Adult|Area Under Curve | 2021-03-01 | NA |
| NCT03053505 | Sejtterapia Kozpont Kft.|University of Debrecen|Kenézy Gyula Korhaz es Rendelointezet|Szabolcs-Szatmar-Bereg Megyei Korhaz es Egyetemi Oktatokorhaz|Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz|Bacs-Kiskun Megyei Korhaz|UD-Genomed Kft. | Clostridium Difficile Infection | 2017-01 | NA |
| NCT01119105 | Nabriva Therapeutics AG | Bacterial Infections|Infection | 2010-05 | PHASE2 |
| NCT06702345 | Leiden University Medical Center|Helmholtz Centre for Infection Research|GlaxoSmithKline|University of Oxford|University of Cologne | C. Difficile|C. Difficile Infection|Controlled Human Infection | 2025-03-01 | NA |
| NCT07084129 | Children´s Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Sepsis | 2026-04 | PHASE1 |
| NCT00124020 | Cumberland Pharmaceuticals | Bacterial Pneumonia | 2005-01 | PHASE3 |
| NCT03961503 | University Hospital, Montpellier | Infective Endocarditis|Infection Related to Ventricular Assist Device|Infection Related to Vascular Prothesis|Surgical Site Infection|Mediastinitis | 2016-01-01 | |
| NCT02692651 | University of Michigan|Merck Sharp & Dohme LLC | Clostridium Difficile Infection (CDI) | 2017-05-01 | PHASE4 |
| NCT01818141 | Hartford Hospital|Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile Infection | 2012-10-17 | PHASE4 |
| NCT05169229 | University Hospital, Linkoeping|Region ?sterg?tland|The Swedish Research Council | Arthroplasty, Replacement, Hip|Osteoarthritis, Hip|Antibiotic Resistant Infection|Prosthetic Joint Infection | 2022-04-01 | PHASE2|PHASE3 |
| NCT01322386 | Stanford University | Primary Sclerosing Cholangitis|Biliary Atresia | 2007-05 | PHASE1 |
| NCT01619982 | Stanford University | Congenital Heart Diseases|Aortic Valve Disorder | 2012-02 | PHASE4 |
| NCT03936998 | Massachusetts General Hospital|Vedanta Biosciences, Inc. | Peanut Allergy | 2019-06-28 | PHASE1|PHASE2 |
| NCT00695903 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Endocarditis, Bacterial|Infective Endocarditis | 2008-09-17 | PHASE2 |
| NCT01199783 | Ruhr University of Bochum | Diabetic Foot | 2011-07 | PHASE3 |
| NCT02374853 | University of Alberta | INFECTION | 2015-03 | PHASE2 |
| NCT01252719 | Melinta Therapeutics, Inc. | Wound Infection|Abscess|Systemic Inflammation|Cellulitis | 2010-12 | PHASE3 |
| NCT01252732 | Melinta Therapeutics, Inc. | Wound Infection|Abscess|Systemic Inflammation|Cellulitis | 2010-12 | PHASE3 |
| NCT04132115 | Azienda Sanitaria-Universitaria Integrata di Udine | Therapeutic Drug Monitoring|Subarachnoid Hemorrhage|Intracerebral Hemorrhage | 2019-10-01 | |
| NCT05831774 | The Methodist Hospital Research Institute | Shoulder Injuries | 2023-06-01 | PHASE4 |
| NCT05777603 | National Cancer Institute (NCI) | Advanced Non Small Cell Lung Cancer | 2024-04-18 | PHASE1 |
| NCT02384200 | University of California, San Diego|Mayo Clinic|University of British Columbia|The Cleveland Clinic|Duke University|Ohio State University|Dartmouth-Hitchcock Medical Center|Vanderbilt University|New York University | Nephrolithiasis|Urinary Tract Infections | 2015-03 | PHASE4 |
| NCT03776409 | First Affiliated Hospital Xi´an Jiaotong University|Second Affiliated Hospital of Xi´an Jiaotong University | Critical Illness | 2018-12-12 | |
| NCT02466698 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s|London Health Sciences Centre | Clostridium Difficile | 2016-08 | PHASE2|PHASE3 |
| NCT01499277 | Pfizer|Forest Laboratories | Complicated Skin and Soft Tissue Infection | 2012-05 | PHASE3 |
| NCT06321796 | Gut-Brain-Axis Therapeutics Inc.|Pitt Hopkins Research Foundation | Pitt Hopkins Syndrome | 2024-02-27 | PHASE2 |
| NCT01419184 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Staphylococcal Skin Infections | 2011-09-09 | PHASE4 |
| NCT04241744 | Creighton University | CDI | 2019-10-29 | PHASE4 |
| NCT03181932 | Savara Inc. | MRSA|Cystic Fibrosis | 2017-09-20 | PHASE3 |
| NCT05655689 | Alexandria University | Bacterial Keratitis|Fungal Keratitis|Mixed Bacterial and Fungal Keratitis|Microbial Keratitis | 2021-12-31 | |
| NCT07120490 | Medical University of Warsaw|Human Biome S.A. | Clostridioides Difficile Infection|Clostridioides Difficile Infection Recurrence|Fecal Microbiota Transplantation (FMT)|Comparative Effectiveness of CDI Treatments|Fidaxomicin|Vancomycin | 2025-10 | NA |
| NCT03408886 | Arizona State University | Autism Spectrum Disorder|Gastrointestinal Disorder | 2018-01-04 | PHASE2 |
| NCT00818766 | Brigham and Women´s Hospital | Antibiotic Prophylaxis | 2008-03 | NA |
| NCT03713528 | OrthoCarolina Research Institute, Inc.|American Association of Hip and Knee Surgeons | Joint Infection | 2020-01-14 | PHASE4 |
| NCT02801656 | Memorial University of Newfoundland | Clostridium Difficile | 2020-12-01 | PHASE3 |
| NCT03452189 | NYU Langone Health | End Stage Renal Disease | 2017-11-27 | PHASE2 |
| NCT02456974 | University Hospital, Ghent|University Hospital, Antwerp|Queen Fabiola Children´s University Hospital (HUDERF+UKZKF) | Pharmacokinetics|Amoxicillin-clavulanate|Piperacillin-tazobactam|Vancomycin|Teicoplanin|Meropenem|Ciprofloxacin|Amikacin | 2012-05 | |
| NCT00396578 | Stony Brook University|Nektar Therapeutics | Ventilator Associated Pneumonia|Respiratory Infection|Tracheobronchitis | 2003-08 | PHASE2 |
| NCT05225558 | LigaChem Biosciences, Inc. | MRSA Bacteremia | 2022-04-26 | PHASE2 |
| NCT03308253 | McMaster University | Surgical Site Infection | 2018-07-16 | PHASE4 |
| NCT04839653 | MEDSI Clinical Hospital 1, ICU | Pneumonia, Ventilator-Associated|Pneumonia|Bloodstream Infection|Sepsis|Respiratory Distress Syndrome|Respiratory Tract Infections|Critical Illness | 2021-05-01 | NA |
| NCT02701595 | University Hospital, Tours | Infective Endocarditis | 2016-02-29 | PHASE3 |
| NCT00445094 | Merck Sharp & Dohme LLC | Infection|Pneumonia | 2006-11 | PHASE4 |
| NCT03402945 | Population Health Research Institute | Surgical Site Infections | 2018-03-05 | PHASE4 |
| NCT06030219 | University of Houston|Paratek Pharmaceuticals Inc | Healthy Volunteers | 2020-10-12 | PHASE1 |
| NCT00428844 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Osteomyelitis | 2007-06-26 | PHASE2 |
| NCT04138706 | McGill University Health Centre+Research Institute of the McGill University Health Centre|Canadian Institutes of Health Research (CIHR) | Clostridium Difficile Infection | 2020-11-19 | PHASE3 |
| NCT02787057 | Peking University First Hospital | Peritoneal Dialysis Associated Peritonitis | 2012-11 | NA |
| NCT06748144 | The Methodist Hospital Research Institute | Lumbar Fusion Surgery | 2026-05 | PHASE2|PHASE3 |
| NCT04872400 | University of Colorado, Denver|Denver Health and Hospital Authority | Fractures, Open|Wounds and Injuries--Infections|Anti-Bacterial Agents|Fractures, Bone|Extremity Fracture Lower|Extremity Fractures Upper | 2021-06-14 | PHASE4 |
| NCT02605213 | Tehran University of Medical Sciences | Primary Sclerosing Cholangitis | 2015-09 | PHASE4 |
| NCT04017468 | Insel Gruppe AG, University Hospital Bern|University Hospital Freiburg | Surgical Site Infection | 2019-10-15 | PHASE2 |
| NCT00426933 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Soft Tissue Infections | 2007-01 | PHASE2 |
| NCT02299882 | Corewell Health West | Lumbar Pain | 2012-08 | NA |
| NCT05338021 | The Affiliated Hospital of Qingdao University | Knee Osteoarthritis | 2022-05-25 | NA |
| NCT00108433 | Pfizer | Bacteremia|Gram-Positive Bacterial Infections | 2005-09 | PHASE3 |
| NCT02307006 | University of Cincinnati|Forest Laboratories | Surgical Site Infection | 2015-01 | PHASE4 |
| NCT06504992 | University of Manitoba|Health Sciences Centre, Winnipeg, Manitoba | Open Fracture|Trauma|Infection, Surgical Site|Fractures, Open|Wound Infection|Fractures, Bone|Post-Operative Wound Infection | 2024-11-01 | PHASE4 |
| NCT00772447 | AstraZeneca | Skin Diseases|Infectious | 2008-09 | PHASE3 |
| NCT05849090 | University of Utah | Infections | 2023-03-27 | EARLY_PHASE1 |
| NCT00035425 | Pfizer | Febrile Neutropenia | 2001-11 | PHASE3 |
| NCT01549613 | University of Cincinnati | Cellulitis|Skin Infections | 2012-05 | PHASE4 |
| NCT05363462 | Universidad Autonoma de Nuevo Leon | Surgical Site Infection|Complication of Surgical Procedure | 2022-01-05 | NA |
| NCT02663596 | Drexel University|The Center for Pediatric Pharmacotherapy, LLC | Pediatric Continuous Renal Replacement Therapy|Dialysis|Renal Failure | 2017-01 | PHASE1 |
| NCT03432858 | WellSpan Health | Carpal Tunnel Syndrome | 2018-05-17 | PHASE4 |
| NCT01720940 | National University Hospital, Singapore|Tan Tock Seng Hospital | Infections Requiring Prolonged Duration (>10 Days) of Vancomycin | 2012-10 | NA |
| NCT00384527 | Romark Laboratories L.C. | Clostridium Infections | 2006-12 | PHASE3 |
| NCT00087490 | Pfizer | Skin+Soft Tissue Infections|Methicillin Resistant Staphylococcus Aureus (MRSA) | 2004-10 | PHASE4 |
| NCT06716749 | Carilion Clinic | Primary Total Knee Arthroplasty|Intraosseous Morphine Injection|Knee Osteoarthritis | 2024-12-01 | PHASE2 |
| NCT02463747 | Tel-Aviv Sourasky Medical Center | Fever|Febrile Neutropenia | 2015-06 | PHASE4 |
| NCT00210899 | Basilea Pharmaceutica | Skin Diseases, Infectious|Skin Diseases, Bacterial|Staphylococcal Skin Infections | 2005-09 | PHASE3 |
| NCT02285140 | Hamilton Health Sciences Corporation|The Physicians´ Services Incorporated Foundation | Thoracic Surgery|Antibiotic Prophylaxis | 2015-04 | NA |
| NCT01515020 | Assistance Publique - H?pitaux de Paris|Novartis | Nosocomial Infection|Healthcare-associated Infection | 2012-05 | PHASE3 |
| NCT01566422 | Vanderbilt University Medical Center | Surgical Site Infection | 2012-06 | NA |
| NCT07221370 | Riverside University Health System Medical Center | Clostridium Difficile Infection|Vancomycin Resistant Enterococci Infection | 2024-10-21 | PHASE2|PHASE3 |
| NCT04648696 | Wake Forest University Health Sciences | Infection | 2021-03-03 | PHASE4 |
| NCT02148601 | Catholic University of the Sacred Heart | Clostridium Difficile | 2013-07 | PHASE2 |
| NCT05156437 | West Virginia University | Endocarditis | 2022-03-16 | PHASE4 |
| NCT00454272 | Sanofi | Infection|Febrile Neutropenia | 2005-01 | PHASE4 |
| NCT04802837 | Summit Therapeutics|Department of Health and Human Services | Clostridioides Difficile Infection | 2021-05-19 | PHASE3 |
| NCT02945241 | Mayo Clinic | Methicillin-resistant Staphylococcus Aureus|Sepsis|Critical Illness | 2014-04 | PHASE1 |
| NCT02504554 | Arizona State University|Northern Arizona University|University of Arizona|University of Minnesota | Gastrointestinal Problems|Autism Spectrum Disorders | 2014-07 | PHASE1|PHASE2 |
| NCT02765256 | University of Pennsylvania|Children´s Hospital of Philadelphia|Crohn´s and Colitis Foundation | Crohn´s Disease | 2016-08 | PHASE2 |
| NCT00281281 | National Taiwan University Hospital | Extracorporeal Membrane Oxygenation | 2005-12 | PHASE4 |
| NCT02570477 | Chinese University of Hong Kong | Clostridium Difficile Infection | 2015-01 | NA |
| NCT04878718 | ProgenaBiome | Autism Spectrum Disorder|Autism | | |
| NCT01764750 | Washington University School of Medicine | Surgical Site Infection | 2013-01 | PHASE1 |
| NCT06426836 | University Hospital, Ghent | Pharmacokinetics|Amoxicillin-clavulanate|Piperacillin-tazobactam|Meropenem|Cefazolin|Teicoplanin|Vancomycin|Ciprofloxacin|Amikacin | 2016-08-19 | NA |
| NCT06889701 | TenNor Therapeutics Inc.|First Affiliated Hospital of Xinjiang Medical University | Periprosthetic Joint Infection (PJI) | 2025-04-03 | PHASE1|PHASE2 |
| NCT04662632 | Osteal Therapeutics, Inc. | Prosthetic Joint Infection | 2021-11-01 | PHASE2 |
| NCT02968693 | Yulin Orthopedics Hospital of Chinese and Western Medicine | Osteomyelitis | 2011-04 | |
| NCT02996487 | Corewell Health East | Clostridium Difficile Infection | 2016-12-19 | PHASE4 |
| NCT05972603 | Independent Public Healthcare Center in Rypin | Osteoarthritis, Knee|Osteoarthritis, Hip|Rheumatoid Arthritis|Avascular Necrosis of Hip | 2022-07-01 | NA |
| NCT01222702 | Actelion | Clostridium Difficile Infection | 2011-01-25 | PHASE2 |
| NCT03273296 | Finnish Institute for Health and Welfare|University of California, San Diego|Brigham and Women´s Hospital | Microbial Colonization | 2017-10-15 | PHASE4 |
| NCT02020031 | Mayo Clinic|Vidacare Corporation | Arthropathy of Knee Joint | 2013-12 | PHASE2|PHASE3 |
| NCT02254967 | Astellas Pharma Europe Ltd.|Merck Sharp & Dohme LLC | Clostridium Difficile | 2014-11-06 | PHASE4 |
| NCT00050401 | Pfizer | Pneumonia | 2002-07 | PHASE3 |
| NCT04856878 | University of Zurich | Central Line-associated Bloodstream Infection (CLABSI)|Catheter-related Bloodstream Infection | 2021-06-01 | PHASE4 |
| NCT01198509 | NYU Langone Health|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Memorial Sloan Kettering Cancer Center | Rheumatoid Arthritis|Psoriatic Arthritis|Periodontal Disease | 2010-01 | NA |
| NCT03880539 | University of Kansas Medical Center|Merck Sharp & Dohme LLC | Clostridium Difficile Infection Recurrence | 2019-06-25 | PHASE4 |
| NCT00925093 | Aarhus University Hospital | Neurosurgery | 2011-09 | PHASE1 |
| NCT06506032 | University Hospital Ostrava|University of Ostrava|Masaryk University|Masaryk Memorial Cancer Institute|Technical University of Ostrava | Post-Sternotomy Deep Sternal Wound Infection | 2021-07-30 | |
| NCT00138112 | Memorial Sloan Kettering Cancer Center | Streptococcal Sepsis|Hematologic Malignancies | 2003-11 | PHASE3 |
| NCT06794944 | Brigham and Women´s Hospital | Inflammatory Bowel Disease (IBD)|Clostridioides Difficile Infection | 2026-09 | PHASE4 |
| NCT07013552 | Medical University of Silesia|Medical Research Agency, Poland | Cardiac Implantable Electronic Device Infections|Infective Endocarditis|Multidrug-resistant Bacteria Screening|Gram Positive Bacterial Infection|Antibiotic Resistant Strain|Antibiotic Therapy|Healthcare Associated Infections | 2025-06 | NA |
| NCT01802073 | Stanford University | Primary Sclerosing Cholangitis | 2012-01 | PHASE3 |
| NCT03759041 | Seres Therapeutics, Inc. | Ulcerative Colitis | 2018-12-19 | PHASE2 |
| NCT01925066 | Seoul National University Hospital|Seoul National University Bundang Hospital | Pneumonia, Staphylococcal|Methicillin-Resistant Staphylococcus Aureus | 2013-08 | PHASE2 |
| NCT05823116 | Aaron Cook|National Institute of Allergy and Infectious Diseases (NIAID) | Vancomycin | 2023-05-22 | PHASE4 |
| NCT02241421 | Maastricht University Medical Center|Top Institute Food and Nutrition | Obesity|Insulin Resistance | 2012-04 | NA |
| NCT03795233 | Boston Medical Center | Clostridium Difficile Infection | 2019-08-23 | PHASE1|PHASE2 |
| NCT06148025 | South Australian Health and Medical Research Institute|Royal Adelaide Hospital|Flinders University|University of Sydney|Telethon Kids Institute|Centenary Institute | Vaccine Response Impaired | 2023-11-23 | PHASE4 |
| NCT04298463 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Hippocrates Research | Acute Bacterial Skin and Skin Structure Infection | 2020-06-18 | |
| NCT05964114 | Erasmus Medical Center | Vancomycin|Pharmacokinetics | 2023-10 | NA |
| NCT01984684 | Melinta Therapeutics, Inc. | Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections | 2014-05 | PHASE3 |
| NCT00175370 | University of British Columbia | Staphylococcal Infections | 2000-09 | NA |
| NCT01104662 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment | 2010-04-19 | PHASE4 |
| NCT03462459 | University of Wisconsin, Madison|Medical College of Wisconsin|Agency for Healthcare Research and Quality (AHRQ)|Henry Ford Hospital|Mayo Clinic | Recurrent Clostridium Difficile Infection|Clostridium Difficile Infection|CDI|C.Difficile Diarrhea|C. Diff Colitis|C.Difficile Colitis | 2018-05-21 | PHASE2 |
| NCT02237859 | Corewell Health West | Clostridium Difficile Infection | 2014-08 | PHASE4 |
| NCT03560440 | Universitaire Ziekenhuizen KU Leuven | Gram-Positive Bacterial Infections | 2014-06 | |
| NCT03817125 | Parker Institute for Cancer Immunotherapy|Seres Therapeutics, Inc. | Metastatic Melanoma | 2019-01-28 | PHASE1 |
| NCT01598311 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile Infection | 2012-05-16 | PHASE3 |
| NCT00107952 | Cumberland Pharmaceuticals | Bacterial Pneumonia | 2005-02 | PHASE3 |
| NCT04948463 | Murdoch Childrens Research Institute | Febrile Neutropenia | 2021-11-15 | PHASE4 |
| NCT06640491 | The Methodist Hospital Research Institute | Total Knee Arthroplasty | 2025-05-15 | PHASE1|PHASE2 |
| NCT06543940 | Mahidol University | AKI - Acute Kidney Injury | 2024-09-01 | NA |
| NCT02590523 | Panhandle Eye Group, LLP | Intracameral Antibiotics|Cataract Surgery|Phacoemulsification|Endophthalmitis|Vancomycin|Moxifloxacin | 2023-01 | PHASE3 |
| NCT02857582 | Per Hellstr?m|Karolinska Institutet|Region G?vleborg | Clostridium Difficile | 2014-10 | PHASE2 |
| NCT05079620 | UConn Health | Aspiration|Aspiration Pneumonia | 2021-11-30 | PHASE4 |
| NCT02227446 | Major Extremity Trauma Research Consortium | Post Operative Surgical Site Infection | 2014-10 | PHASE3 |
| NCT04297176 | Hamad Medical Corporation|Qatar University | Infection, Bacterial | 2020-01-23 | NA |
| NCT00228410 | Wyeth is now a wholly owned subsidiary of Pfizer | Skin Diseases, Infectious | 2002-11 | PHASE3 |
| NCT05705843 | The Methodist Hospital Research Institute | Infection, Surgical Site | 2023-01-25 | PHASE4 |
| NCT05959603 | Rabin Medical Center | Infection | 2020-05-31 | PHASE3 |
| NCT01162733 | Christiana Care Health Services | Infectious Disease | 2010-07 | NA |
| NCT03456544 | Peking University First Hospital | Vancomycin|Staphylococcal Infections|Adverse Effect|Acute Kidney Injury|Cross-sectional Study | 2018-10-31 | |
| NCT01570192 | University of Florida | Bacterial Pneumonia | 2010-09 | PHASE2 |
| NCT01798537 | Rambam Health Care Campus | Bacteremia Associated With Intravascular Line|Ventilator Associated Pneumonia|Bacteremia | 2013-06 | PHASE2|PHASE3 |
| NCT02027532 | University of Tennessee | Infection|Closed Fractures | 2009-10 | NA |
| NCT03476317 | Children´s Hospital of Philadelphia|University of Pennsylvania|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Crohn Disease | 2018-07-12 | PHASE2 |
| NCT00572559 | Pfizer | Pneumonia, Ventilator-Associated | 2002-11 | PHASE4 |
| NCT06336824 | Clinical Research Centre, Malaysia | Staphylococcus Aureus Bacteremia | 2024-06-28 | PHASE3 |
| NCT01626560 | Hospital Universitario Evangelico de Curitiba | Cellulitis | 2012-07 | PHASE4 |
| NCT02790996 | PENTA Foundation|St George´s, University of London|Hopital Universitaire Robert-Debre|University of Tartu|Consorzio per Valutazioni Biologiche e Farmacologiche|University of Liverpool|Therakind limited|Bambino Gesù Hospital and Research Institute|Servicio Madrile?o de Salud, Madrid, Spain|Aristotle University Of Thessaloniki|Cardiff University|SYNAPSE Research Management Partners S.L|European Commission | Late Onset Neonatal Sepsis | 2017-02-27 | PHASE2 |
| NCT06161870 | Central South University | Severe Infection | 2021-01-01 | PHASE4 |
| NCT02839486 | Bambino Gesù Hospital and Research Institute | Congenital Heart Disease | 2017-10-01 | |
| NCT02814916 | AbbVie | Methicillin-Resistant Staphylococcus Aureus|Bacterial Infections|Staphylococcal Skin Infections | 2017-03-30 | PHASE3 |
| NCT05975671 | Children´s Hospital of Philadelphia|Children´s Healthcare of Atlanta|St. Louis Children´s Hospital|Johns Hopkins University|University of Pennsylvania|Centers for Disease Control and Prevention | Sepsis|Sepsis Mrsa|Sepsis Bacteremia|Antimicrobial - Induced Nephropathy|Sepsis, Severe|Septic Shock|Septic Syndrome | 2023-08-21 | NA |
| NCT04042233 | The Methodist Hospital Research Institute | Prosthetic Joint Infection|Vancomycin|Joint Diseases | 2019-12-31 | PHASE4 |
| NCT01820026 | University of Roma La Sapienza | Cirrhosis | 2012-12 | PHASE4 |
| NCT01037192 | Fraser Health | Skin and Soft Tissue Infections | 2010-03 | NA |
| NCT01757236 | University Hospital, Tours|Pfizer|International Clinical Trials Association | Hip Prosthetic Joint Infection | 2012-10 | PHASE2 |
| NCT01175707 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Complicated Skin or Skin Structure Infection | 2010-07-15 | PHASE4 |
| NCT02600611 | Motif Bio | Skin Structures and Soft Tissue Infections | 2015-11-01 | PHASE3 |
| NCT01283581 | Melinta Therapeutics, Inc. | Skin and Subcutaneous Tissue Bacterial Infections | 2011-01 | PHASE2 |
| NCT07201987 | Ganesh M. Shankar | Spine Surgery|Postoperative Pain Management | 2027-01-01 | PHASE2 |
| NCT03453684 | University of Colorado, Denver | Surgical Site Infection|Vancomycin | 2012-12-01 | PHASE4 |
| NCT01922011 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Acute Hematogenous Osteomyelitis | 2013-09-13 | PHASE3 |
| NCT05266807 | Benoit Guery | Clostridioides Difficile Infection | 2023-03-15 | PHASE3 |
| NCT00871104 | Juan A. Arnaiz | Infective Endocarditis | 2009-07 | PHASE4 |
| NCT04983901 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm | 2021-09-14 | PHASE2 |
| NCT00355602 | University of Dundee|Tenovus Scotland | Colitis, Ulcerative | 2006-07 | NA |
| NCT01191840 | Duke University|National Institutes of Health (NIH) | Bacteremia | 2011-02 | PHASE2 |
| NCT02137668 | Sacramento Pediatric Gastroenterology | Primary Sclerosing Cholangitis|Biliary Atresia | 2010-07 | PHASE1 |
| NCT06050785 | Assiut University | Anterior Cruciate Ligament Injuries | 2024-02-01 | |
| NCT05625373 | Women and Infants Hospital of Rhode Island | Postoperative Complications | 2022-10-25 | PHASE2|PHASE3 |
| NCT01786161 | Massachusetts General Hospital | MRSA - Methicillin Resistant Staphylococcus Aureus Infection | 2013-09 | PHASE4 |
| NCT02660346 | Sharp HealthCare | Bacteremia | 2015-11 | PHASE4 |
| NCT02202135 | Pfizer|Forest Laboratories | Complicated Skin and Soft Tissue Infection | 2014-06 | PHASE3 |
| NCT01427842 | The Canberra Hospital | Vancomycin Therapy | 2011-08 | PHASE2 |
| NCT06651268 | Liaquat National Hospital & Medical College | Wound Complication|Cardiac Surgery | 2024-11-01 | PHASE1|PHASE2 |
| NCT01346059 | Corewell Health East | Colitis | 2011-04 | NA |
| NCT01597505 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile Infection | 2012-05-16 | PHASE3 |
| NCT05697965 | Assiut University | Arthroplasty Complications|Periprosthetic Fracture of Hip | 2023-03-01 | PHASE2 |
| NCT07207434 | Aga Khan University|Bill and Melinda Gates Foundation|International Centre for Diarrhoeal Disease Research, Bangladesh|University of Zambia|Institut Pasteur de Dakar | Environmental Enteric Dysfunction (EED)|Stunting | 2025-08-30 | PHASE2 |
| NCT02037295 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 2014-01-14 | PHASE2 |
| NCT02051595 | University of Florida | Infection | 2014-04 | EARLY_PHASE1 |
| NCT03466502 | University of Nevada, Reno|Renown Regional Medical Center | Clostridium Difficile Infection | 2018-03-08 | PHASE4 |
| NCT03466645 | Isfahan University of Medical Sciences | Elective Craniotomy-candidated Patients | 2018-04-01 | PHASE1|PHASE2 |
| NCT02686645 | Queen Elizabeth II Health Sciences Centre | Clostridium Difficile Infection | 2016-12 | PHASE2|PHASE3 |
| NCT00296049 | Wake Forest University Health Sciences|National Cancer Institute (NCI) | Infection|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific | 2005-07 | NA |
| NCT06601257 | University of Michigan | Pharmacokinetics and Pharmacodynamics | 2025-04-01 | PHASE1 |
| NCT00468728 | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Infections|Diarrhea | 2006-10-04 | PHASE3 |
| NCT03557008 | Emory University | Rabies Human | 2018-07-05 | PHASE4 |
| NCT00427076 | Rabin Medical Center | Staphylococcal Infections|Meningitis|Sepsis|Pneumonia | 2007-06 | PHASE3 |
| NCT01819935 | Pfizer | Pneumonia | 2012-12 | |
| NCT01645735 | Forest Laboratories|AstraZeneca | Infections | 2012-10 | PHASE4 |
| NCT06197308 | University of Minnesota | Primary Sclerosing Cholangitis | 2024-03-01 | EARLY_PHASE1 |
| NCT04075526 | NYU Langone Health | Osteoarthritis | 2019-10-01 | PHASE1 |
| NCT07283068 | The Methodist Hospital Research Institute | Revision Total Knee Arthroplasty | 2026-06-15 | NA |
| NCT05709184 | Rambam Health Care Campus|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|European Institute of Oncology|University of Alberta|Imperial College London|University of Debrecen|Lithuanian University of Health Sciences | Clostridioides Difficile Infection | 2023-11-15 | NA |
| NCT01509339 | Case Western Reserve University|Cystic Fibrosis Foundation | Cystic Fibrosis|Methicillin-resistant Staphylococcus Aureus | 2012-01 | PHASE1 |
| NCT01085591 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Clostridium Difficile Infection|Diarrhea | 2010-04-01 | PHASE2 |
| NCT06126731 | Institute of Cancer Research, United Kingdom|Prostate Cancer Foundation | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2023-11-02 | PHASE1|PHASE2 |
| NCT03688659 | Assiut University | Infective Endocarditis | 2019-01-01 | NA |
| NCT04132427 | Arizona State University|Pitt Hopkins Research Foundation | Pitt Hopkins Syndrome | 2019-09-30 | PHASE2 |
| NCT07328971 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Clostridia Difficile Colitis | 2026-04-24 | PHASE3 |
| NCT03046901 | Ochsner Health System | Primary Sclerosing Cholangitis|Post- Orthotopic Liver Transplantation | 2016-12-07 | NA |
| NCT04500275 | National Cheng-Kung University Hospital | Sternal Wound Infection | 2020-07-01 | PHASE4 |
| NCT02218372 | Astellas Pharma Europe B.V.|Merck Sharp & Dohme LLC | Clostridium Difficile-associated Diarrhea (CDAD) | 2015-01-09 | PHASE3 |
| NCT05276687 | Assiut University | Surgical Wound Infection | 2022-09 | PHASE4 |
| NCT04793152 | Anthony Bai|Physician Services Incorporated|Canadian Institutes of Health Research (CIHR) | MRSA | 2023-03-20 | NA |